Intravitreal bevacizumab for exudative age-related macular degeneration: Effect on different subfoveal membranes

Retina

Volumn 30, Issue 9, 2010, Pages 1426-1431

  Tao, Yong ^a,b   Jonas, Jost B ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Avastin; exudative age related macular degeneration; intraocular neovascularization; intravitreal bevacizumab

Indexed keywords

BEVACIZUMAB;

AGED; ARTICLE; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; EXUDATES AND TRANSUDATES; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOVEA CENTRALIS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; OPHTHALMOSCOPY; PROGNOSIS; RETINAL DETACHMENT; RETINAL NEOVASCULARIZATION; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TONOMETRY, OCULAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 78049259987     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181d5e964     Document Type: Article

References (42)

1. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevaci-zumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36: 331-335. (Pubitemid 41073112)
2. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113: 363-372.e5.
3. Emerson MV, Lauer AK, Flaxel CJ, et al. Intravitreal bev-acizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 2007;27:439-444. (Pubitemid 46624283)
4. Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular generation. Retina 2007;27:432-438. (Pubitemid 46624282)
5. Chen CY, Wong TY, Heriot WJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: A short-term study. Am J Ophthalmol 2007;143:510-512. (Pubitemid 46298546)
6. Stifter E, Michels S, Prager F, et al. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage. Am J Ophthalmol 2007;144: 886-892. (Pubitemid 350122341)
7. Algvere PV, Steen B, Seregard S, Kvanta A. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol 2008;86:482-489. (Pubitemid 351850187)
8. Azad RV, Khan MA, Chanana B, Azad S. Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to age-related macular degeneration in an Indian population. Jpn J Ophthalmol 2008;52:52-56. (Pubitemid 351462226)
9. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: A one-year prospective study. Am J Ophthalmol 2008;145:249-256.
10. Cleary CA, Jungkim S, Ravikumar K, Kelliher C, Acheson RW, Hickey-Dwyer M. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6-and 9-month results. Eye 2008;22:82-86.
11. Fong KC, Kirkpatrick N, Mohamed Q, Johnston RL. Intra vitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment. Clin Experiment Ophthalmol 2008;36:748-755.
12. Goverdhan SV, Lochhead J. Submacular haemorrhages after intravitreal bevacizumab for large occult choroidal neovas-cularisation in age-related macular degeneration. Br J Ophthalmol 2008;92:210-212. (Pubitemid 351224096)
13. Melamud A, Stinnett S, Fekrat S. Treatment of neovascular age-related macular degeneration with intravitreal bevacizu-mab: efficacy of three consecutive monthly injections. Am J Ophthalmol 2008;146:91-95.
14. Ip MS, Scott IU, Brown GC, et al; American Academy of Ophthalmology. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: A report by the American Academy of Ophthalmology. Ophthalmology 2008;115:1837-1846.
15. Arias L, Caminal JM, Casas L, et al. A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Br J Ophthalmol 2008;92:1636-1641.
16. Jonas JB, Ihloff AK, Harder B, et al. Intravitreal bevacizumab versus triamcinolone acetonide for exudative age-related macular degeneration. Ophthalmic Res 2009;41:21-27. (Pubitemid 46358803)
17. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascular-ization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351: 2805-1816.
18. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431. (Pubitemid 44511557)
19. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355: 1432-1444. (Pubitemid 44511558)
20. Miller JW, Schmidt-Erfurth U, Sickenberg M, et al. Photo-dynamic therapy with verteporfin for choroidal neovasculari-zation caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol 1999;117:1161-1173. (Pubitemid 29428826)
21. Schmidt-Erfurth U, Miller JW, Sickenberg M, et al. Photo-dynamic therapy with verteporfin for choroidal neovasculari-zation caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch Ophthalmol 1999; 117:1177-1187. (Pubitemid 29428826)
22. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999;117:1329-1345.
23. Jonas JB, Libondi T, Ihloff AK, et al. Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type. Acta Ophthalmol Scand 2007;85:563-565. (Pubitemid 47163119)
24. Holladay JT. Visual acuity measurements. J Cataract Refract Surg 2004;30:287-290.
25. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR; MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;l 14:246-252 (Pubitemid 46172497)
26. Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 2007;144:850-857. (Pubitemid 350130239)
27. Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J; Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR) Research Group. Improved vision-related function after ranibizumab vs photodynamic therapy: A randomized clinical trial. Arch Ophthalmol 2009;127:13-21.
28. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65.
29. Khetpal V, Heimmel MR, Rao SK, Scott IU, Greenberg PB. Resolution of retinal pigment epithelial detachment associated with exudative age-related macular degeneration following intra-vitreal ranibizumab therapy. Acta Ophthalmol 2009;87:115-116.
30. Cohen SY, Dubois L, Tadayoni R, et al. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol 2009;148: 409-413.
31. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2009. [Epub ahead of print].
32. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58.el.
33. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;142:l-9. (Pubitemid 43946791)
34. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA Jr, Scott IU. Intravitreal bevacizumab for choroidal neovascula-rization caused by AMD (IBeNA Study): results of a phase 1 doseescalation study. Invest Ophthalmol Vis Sci 2006;47: 4569-4578. (Pubitemid 46579387)
35. Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neo-vascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007;245:68-73. (Pubitemid 46766732)
36. Lommatzsch A, Heimes B, Gutfleisch M, Spital G, Zeimer M, Pauleikhoff D. Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments. Eye 2009;23:2163-2168.
37. Furino C, Boscia F, Recchimurzo N, et al. Intravitreal bevacizumab for treatment-näive subfoveal occult choroidal neovascularization in age-related macular degeneration. Acta Ophthalmol 2009;87:404-407.
38. Bashshur ZF, Haddad ZA, Schakal AR, Jaafar RF, Saad A, Noureddin BN. Intravitreal bevacizumab for treatment of neo-vascular age-related macular degeneration: the second year of a prospective study. Am J Ophthalmol 2009;148:59-65.el.
39. Arevalo JF, Fromow-Guerra J, Sanchez JG, et al; Pan-American Collaborative Retina Study Group. Primary intra-vitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. Retina 2008;28:1387-1394.
40. Ghazi NG, Knape RM, Kirk TQ, Tiedeman JS, Conway BP. Intravitreal bevacizumab (Avastin) treatment of retinal angi-omatous proliferation. Retina 2008;28:689-695.
41. Yoganathan P, Deramo VA, Lai JC, Tibrewala RK, Fastenberg DM. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 2006;26:994-998. (Pubitemid 44973217)
42. Aisenbrey S, Ziemssen F, Völker M, et al. Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007;245:941-948 (Pubitemid 46979534)